The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 2, 2014, Pages 218-230

  Huang, Peixin ^a   Xu, Xiaojing ^b   Wang, Lingyan ^a   Zhu, Bijun ^b   Wang, Xiangdong ^a,c   Xia, Jingling ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c Shanghai Research Institute   (China)

Author keywords

CXCL5; CXCL8; EGF; EGFR; Hepatocellular carcinoma; Migration; Proliferation

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CHEMOKINE RECEPTOR CXCR2; CXCL5 PROTEIN, HUMAN; DACTOLISIB; EGFR PROTEIN, HUMAN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; IL8 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE;

ARTICLE; CELL MOTION; CELL PROLIFERATION; CXCL5; CXCL8; DRUG ANTAGONISM; EGF; EGFR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIGRATION; PATHOLOGY; PHOSPHORYLATION; PROLIFERATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

CXCL5; CXCL8; EGF; EGFR; HEPATOCELLULAR CARCINOMA; MIGRATION; PROLIFERATION;

BUTADIENES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL5; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INFLAMMATION; INTERLEUKIN-8; LIVER NEOPLASMS; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; QUINOLINES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84893669713     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12153     Document Type: Article

References (52)

1. Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009; 4: 353-67.
2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005; 2: 143-54.
3. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 7203: 436-44.
4. Wang X, Sun Z, Andersson R. Autohepatocyte transplantation in a degradable collagen device in the bursa omentalis. Transplant Proc. 1999; 5: 2138-42.
5. Qin LX. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron. 2012; 3: 203-9.
6. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011; 1: 35-43.
7. Wu WY, Li J, Wu ZS, et al. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer. 2011; 11: 506.
8. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010; 3: 370-9.
9. Berasain C, Perugorria MJ, Latasa MU, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009; 7: 713-25.
10. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012; 1: 33-40.
11. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005; 2: 307-14.
12. Liu H, Pan Z, Li A, et al. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol. 2008; 5: 373-8.
13. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009; 12: 2766-70.
14. Shirabe K, Mano Y, Muto J, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today. 2012; 1: 1-7.
15. Tian J, Tang ZY, Ye SL, et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999; 5: 814-21.
16. Zhang Y, Wang L, Zhang M, et al. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol. 2012; 1: 35-43.
17. Finot F, Masson R, Desmots F, et al. Combined stimulation with the tumor necrosis factor alpha and the epidermal growth factor promotes the proliferation of hepatocytes in rat liver cultured slices. Int J Hepatol. 2012; 2012: 785-6.
18. Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007; 43: 17081-6.
19. Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007; 9: 770-87.
20. Breindel JL, Haskins JW, Cowell EP, et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013; 16: 5053-65.
21. Masuda H, Zhang D, Bartholomeusz C, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 2: 331-45.
22. Buckley AF, Burgart LJ, Sahai V, et al. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008; 2: 245-51.
23. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001; 10: 1377-83.
24. Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry-Us. 1987; 5: 1443-51.
25. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7: 505-16.
26. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006; 27: 3787-800.
27. Ogunwobi OO, Wang T, Zhang L, et al. Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2012; 3: 566-78.
28. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 11: 1160-74.
29. Xu X, Xia J, Wang X. Potential anticancer therapies via CXCL5 and its receptors. Expert Rev Clin Pharmacol. 2012; 5: 347-50.
30. Alanazi I, Ebrahimie E, Hoffmann P, et al. Combined gene expression and proteomic analysis of EGF induced apoptosis in A431 cells suggests multiple pathways trigger apoptosis. Apoptosis. 2013 [Epub ahead of print].
31. Kawamura M, Toiyama Y, Tanaka K, et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012; 14: 2244-51.
32. Gantsev SK, Umezawa K, Islamgulov DV, et al. The role of inflammatory chemokines in lymphoid neoorganogenesis in breast cancer. Biomed Pharmacother. 2013; 67: 363-6.
33. Zhang H, Xia W, Lu X, et al. A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients. PLoS ONE. 2013; 8: e57830.
34. Yuan A, Chen J, Yao P, et al. The role of IL-8 in cancer cells and microenvironment interaction. Front Biosci. 2005; 10: 853-65.
35. Ren Y, Poon RT, Tsui HT, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003; 16(Pt 1): 5996-6001.
36. Wang Y, Wang W, Wang L, et al. Regulatory mechanisms of interleukin-8 production induced by tumour necrosis factor-alpha in human hepatocellular carcinoma cells. J Cell Mol Med. 2012; 3: 496-506.
37. Gangavarapu P, Rajagopalan L, Kolli D, et al. The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment. J Leukoc Biol. 2012; 91: 259-65.
38. Kubo F, Ueno S, Hiwatashi K, et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005; 12: 800-7.
39. Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012; 6: 2242-54.
40. Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005; 1: 2005-10.
41. Sun D, Sun B, Liu T, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med. 2013; 8: 1038-47.
42. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011; 1: 159-68.
43. Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 2011; 1: 91-9.
44. Liu Z, Yang L, Xu J, et al. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res. 2011; 2: 241-6.
45. Ning Y, Labonte MJ, Zhang W, et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther. 2012; 6: 1353-64.
46. Singh JK, Farnie G, Bundred NJ, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res. 2013; 3: 643-56.
47. Luppi F, Longo AM, de Boer WI, et al. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer-J Iaslc. 2007; 1: 25-33.
48. Wang XD. Role of clinical bioinformatics in the development of network-based Biomarkers. J Clin Bioinforma. 2011; 1: 28.
49. Wang XD, Liotta L. Clinical bioinformatics: a new emerging science. J Clin Bioinforma. 2011; 1: 1.
50. Abraham E, Marincola FM, Chen ZN, et al. Clinical and translational medicine: integrative and practical science. Clin Transl Med. 2012; 1: 1.
51. Wang XD, Marincola FM. A decade plus of translation: what do we understand? Clin Transl Med. 2012; 1: 3.
52. Zheng Y, Zhang M, Qian M, et al. Genetic comparison of mouse lung telocytes with mesenchymal stem cells and fibroblasts. J Cell Mol Med. 2013; 17: 567-77.